Edrecolomab ELISA Kit

Catalog No.

KDD17401

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant Human CD326 has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Edrecolomab present is bound by the immobilized protein. After washing away any unbound substances, a HRP conjugated probe is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Edrecolomab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Edrecolomab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.63 - 1,000 ng/mL

Sensitivity

3.11 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

17-1A, CAS: 156586-89-9

Background

Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.